Heat Biologics (HTBX) Announces Preclinical Data from ComPACT Study; Amplified CDS+ T Cells, MPECs Noted

November 14, 2016 7:02 AM EST
Get Alerts HTBX Hot Sheet
Trade HTBX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Heat Biologics, Inc. (Nasdaq: HTBX) announced that preclinical data from its ComPACT platform, a single product that combines Heat’s ImPACT therapeutic vaccine with an immune co-stimulatory molecule, was presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. In the poster, “Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-IBBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory and Tumor Elimination,” researchers assessed ComPACT/OX40L in a third preclinical mouse tumor model: colorectal cancer (MC38). ComPACT/OX40L amplified antigen-specific CD8+ T cells and memory precursor effector cells (MPECs). It also blocked tumor growth, and increased both tumor rejection and animal survival, generating better results than an OX40 antibody, and without the broad systemic inflammation typically seen with OX40 antibody therapy. Furthermore, ComPACT/OX40L, combined with either PD1 or PD-L1 blocking antibodies, produced even greater antitumor immunity than either compound alone.

The researchers concluded that ComPACT synergizes well with checkpoint inhibitors, which could provide an effective cancer treatment approach in humans.

These studies expand on previous ComPACT studies, which demonstrated anti-tumor efficacy of ComPACT/OX40L in two mouse models: colon cancer and melanoma, where it was attributed to amplified antigen-specific CD8+ T cell expansion (Fromm et. al. Cancer Immunology Research. 2016).

“These data provide a compelling mechanistic rationale for combinations between ComPACT vaccines and PD-1/L1 blockade,” said Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer, and a study author. “The combination significantly increased the frequency of tumor-antigen specific CD8+ T cells, and increased the fraction of those cells that are most likely to become long-lived memory cells capable of providing durable tumor immunity.”

The poster is available in the Publications section of Heat’s corporate website.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA, Management Comments

Add Your Comment